This is an innovative assay in the field of Oncology.
This new test consists of a panel that includes 1021 genes and analyzes two important biomarkers, MSI and TMB, related to immunotherapy. In addition, it offers analysis of the Loss of Heterozygosity (LOH) phenomenon, which can be used as a biomarker for the selection of PARP inhibitors as part of therapy, allowing the physician to design an individualized treatment for the patient. This approach includes options such as immunotherapy, chemotherapy, PARP inhibitors, and participation in clinical trials.
In addition, prime DX Liquid analyzes genes associated with genetic predisposition to cancer, providing the physician with information about the patient’s potential for hereditary cancer syndrome.